Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 4/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924048 | 0.91 | HCRTR2 (0.42) | NR1H2NR1H3STSPARP1HCRTR2 | |
| SCHEMBL30924050 | 0.91 | HCRTR2 (0.42) | NR1H2NR1H3STSPARP1HCRTR2 | |
| SCHEMBL30923959 | 0.90 | STS (0.40) | NR1H2NR1H3STSPARP1HCRTR2 | |
| SCHEMBL27219736 | 0.89 | MMP1 (0.35) | HCRTR2 | |
| SCHEMBL30924028 | 0.81 | NR1H2 (0.39) | NR1H2NR1H3STSPARP1GHSR | |
| SCHEMBL30957911 | 0.81 | PARP1 (0.40) | NR1H2NR1H3STSPARP1GHSR | |
| SCHEMBL30923948 | 0.81 | PARP1 (0.40) | NR1H2NR1H3STSPARP1GHSR | |
| SCHEMBL27220018 | 0.79 | MMP1 (0.36) | HCRTR2TACR1 | |
| SCHEMBL27219995 | 0.78 | MMP1 (0.36) | HCRTR2PTPN1 | |
| SCHEMBL30923995 | 0.76 | NR1H2 (0.36) | NR1H2NR1H3STSPARP1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-27 | — | — | US | disclosed |
| EP-4612145-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-09-10 | — | — | EP | disclosed |
| US-20240317765-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| WO-2024095133-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317765-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | NR1H2 170/4885NR1H3 225/4885STS 1342/4885 |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | NR1H2 170/4885NR1H3 225/4885STS 1342/4885 |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | HCRTR2, HCRTR1, NPY1R | NR1H2 79/4885NR1H3 86/4885STS 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.